The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.
This document outlines the methods used in the COVID-19 vaccines effectiveness and impact studies review.
The Vaccine Economics Research for Sustainability and Equity (VERSE) project evaluated the status of vaccine coverage and equity status in the Democratic Republic of the Congo in 2013. Note: This resource is in French.
The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.
The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.
In partnership with the Asian Development Bank, IVAC developed factsheets and newsletters summarizing key measures for COVID-19 vaccines.
The Vaccine Economics Research for Sustainability and Equity (VERSE) project evaluated the status of vaccine coverage and equity status in Rwanda in 2019.
The Vaccine Economics Research for Sustainability and Equity (VERSE) project evaluated the status of vaccine coverage and equity status in South Africa in 2016.
This document outlines the methods used in the VIEW-hub data collection and data update process.
The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.